Core Insights - Orthofix Medical Inc. reported a Q3 2025 EPS of -$0.57, missing the estimated EPS of $0.12, but exceeded revenue expectations with approximately $205.6 million [1][5] - The company has adjusted its full-year 2025 net sales guidance and increased the lower end of its adjusted EBITDA guidance, indicating a strategic approach to future growth [2][5] Financial Performance - The negative price-to-earnings (P/E) ratio of -4.88 indicates negative earnings, while the price-to-sales ratio of 0.75 suggests the stock is valued at 75 cents for every dollar of sales [3][5] - The enterprise value to sales ratio is 0.92, reflecting the company's valuation in relation to its revenue [3] - The enterprise value to operating cash flow ratio is 25.92, showing how many times the operating cash flow can cover the enterprise value [4] - An earnings yield of approximately -20.50% emphasizes the negative earnings [4] - The debt-to-equity ratio of about 0.45 indicates a moderate level of debt compared to equity [4][5] - A current ratio of 2.67 suggests a robust ability to cover short-term liabilities with short-term assets [4][5] Strategic Considerations - The company is navigating challenges, including the discontinuation of its M6™ product lines, while its revenue performance and financial adjustments signal a strategic approach to future growth [4]

PresentationHello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Orthofix Third Quarter 2025 Earnings Conference Call. [Operator Instructions]Julie DeweyChief Investor Relations & Communications Officer Thank you, operator, and good morning, everyone. Welcome to Orthofix' Third Quarter 2025 Earnings Call. We appreciate you joining us. I'm Julie Dewey, Orthofix' Chief IR and Communications Officer. Joining ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Orthofix Medical (NasdaqGS:OFIX) Q3 2025 Earnings Call November 04, 2025 08:30 AM ET Speaker1Thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Orthofix Third Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star then ...

Orthofix (OFIX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +66.67%. A quarter ago, it was expected that this medical device maker would post earnings of $0.04 per share when it actually produced earnings of $0.13, delivering a surprise of +225%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisd ...

Pro Forma Financial Results Results excluding the impact of discontinuation of M6 product lines Net Sales by Major Product Category by Reporting Segment | | | | | Three Months Ended September | 30, | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | Constant | | | | | | | | Currency | | (Unaudited, U.S. Dollars, in millions) | | 2025 | | 2024 | Change | Change | | Bone Growth Therapies | $ | 61.2 | $ | 57.9 | 5.7% | 5.7% | | Spinal Implants, Biologics and Enabling Technologies* | | 108.6 | | 102.9 ...

Exhibit 99.1 News Release Orthofix Reports Third Quarter 2025 Financial Results LEWISVILLE, Texas — November 4, 2025 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's de ...

Core Viewpoint - Investors in the Medical - Instruments sector should consider Fresenius (FMS) and Orthofix (OFIX) for potential value opportunities, with FMS currently showing stronger indicators for value investment [1]. Valuation Metrics - Fresenius has a Zacks Rank of 1 (Strong Buy), indicating a more favorable earnings estimate revision trend compared to Orthofix, which has a Zacks Rank of 3 (Hold) [3]. - FMS has a forward P/E ratio of 11.80, significantly lower than OFIX's forward P/E of 26.24, suggesting that FMS may be undervalued [5]. - The PEG ratio for FMS is 0.61, while OFIX's PEG ratio is 2.62, indicating that FMS is expected to grow earnings at a more favorable rate relative to its price [5]. - FMS has a P/B ratio of 0.96, compared to OFIX's P/B of 1.22, further supporting the notion that FMS is undervalued relative to its book value [6]. Investment Outlook - The improving earnings outlook for FMS enhances its attractiveness as a value investment, positioning it as the superior option compared to OFIX based on current valuation metrics [7].

Group 1: Rewey Asset Management Overview - Rewey Asset Management's "RAM Smid Composite" increased by 6.11% in Q2 2025, slightly underperforming the benchmark Russell 2500 Value Total Return Index, which gained 7.29% [1] - Year-to-date, the composite returned -1.29%, compared to a 1.03% gain for the benchmark [1] - The firm expresses confidence in the Smid value sector as it approaches the second half of 2025 [1] Group 2: Orthofix Medical Inc. Analysis - Orthofix Medical Inc. (NASDAQ:OFIX) is highlighted as a key stock, with a one-month return of 2.76% and a 52-week loss of 9.80% [2] - As of September 12, 2025, Orthofix's stock closed at $14.91 per share, with a market capitalization of $588.86 million [2] - Rewey Asset Management increased its position in Orthofix Medical Inc. in Q2 2025, following a 45.6% decline from its February high and a 36.1% drop from its 2024 close, viewing it as a compelling valuation opportunity [3] Group 3: Hedge Fund Interest and Comparisons - Orthofix Medical Inc. was held by 25 hedge fund portfolios at the end of Q2 2025, down from 28 in the previous quarter [4] - While Orthofix is acknowledged for its investment potential, the firm believes certain AI stocks present greater upside potential and less downside risk [4]